Evaluating the evidence for angiotensin II for the treatment of vasoplegia in critically ill cardiothoracic surgery patients

J Thorac Cardiovasc Surg. 2022 Apr;163(4):1407-1414. doi: 10.1016/j.jtcvs.2021.02.097. Epub 2021 Mar 19.

Authors

Jonathan H Chow¹, Erica D Wittwer², Patrick M Wieruszewski², Ashish K Khanna³

Affiliations

¹ Anesthesiology and Critical Care Medicine, George Washington University School of Medicine, Washington, DC.
² Anesthesiology & Critical Care Medicine, Mayo Clinic School of Medicine, Rochester, Minn.
³ Section on Critical Care Medicine, Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, NC; Outcomes Research Consortium, Cleveland, Ohio. Electronic address: akhanna@wakehealth.edu.

PMID: 33875258
DOI: 10.1016/j.jtcvs.2021.02.097

No abstract available

Keywords: angiotensin II; postcardiopulmonary bypass vasoplegia; shock.

Publication types

Editorial

MeSH terms

Angiotensin II / therapeutic use*
Cardiopulmonary Bypass*
Clinical Trials as Topic
Critical Illness
Extracorporeal Membrane Oxygenation
Humans
Postoperative Complications / drug therapy
Vasoconstrictor Agents / therapeutic use*
Vasoplegia / drug therapy*
Vasoplegia / etiology

Substances

Vasoconstrictor Agents
Angiotensin II